Skip to main content
Top
Published in: Clinical and Molecular Allergy 1/2018

Open Access 01-12-2018 | Research

Comorbidities are associated with different features of severe asthma

Authors: Federica Novelli, Elena Bacci, Manuela Latorre, Veronica Seccia, Maria Laura Bartoli, Silvana Cianchetti, Federico Lorenzo Dente, Antonella Di Franco, Alessandro Celi, Pierluigi Paggiaro

Published in: Clinical and Molecular Allergy | Issue 1/2018

Login to get access

Abstract

Background

According to ATS/ERS document on severe asthma (SA), the management of these patients requires the identification and proper treatment of comorbidities, which can influence the control of asthma.

Methods

The aim of this study was to assess the independent effect of different comorbidities on clinical, functional and biologic features of SA. Seventy-two patients with SA according to GINA guidelines were examined. We collected demographic data, smoking habit, asthma history, and assessment of comorbidities. Pulmonary function, inflammatory biomarkers, upper airway disease evaluation, asthma control and quality of life were carefully assessed.

Results

The mean age of patients was 59.1 years (65.3% female, 5.6% current smokers). Comorbidities with higher prevalence were: chronic rhinosinusitis with or without nasal polyps (CRSwNP or CRSsNP), obesity and gastro-esophageal reflux (GERD), with some overlapping among them. In an univariate analysis comparing patients with single comorbidities with the other ones, asthmatics with CRSwNP had lower lung function and higher sputum eosinophilia; obese asthmatics had worse asthma control and quality of life, and tended to have lower sputum eosinophils; asthmatics with GERD showed worse quality of life. In multivariate analysis, obesity was the only independent factor associated with poor asthma control (OR 4.9), while CRSwNP was the only independent factor associated with airway eosinophilia (OR 16.2). Lower lung function was associated with the male gender and longer duration of asthma (OR 3.9 and 5.1, respectively) and showed a trend for the association with nasal polyps (OR 2.9, p = 0.06).

Conclusion

Our study suggests that coexisting comorbidities are associated with different features of SA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.CrossRef Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.CrossRef
2.
go back to reference Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73:116–24.CrossRef Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73:116–24.CrossRef
3.
go back to reference Van Ganse E, Antonicelli L, Zhang Q, Laforest L, Yin DD, Nocea G, Sazonov Kocevar V. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med. 2006;100:140–7.CrossRef Van Ganse E, Antonicelli L, Zhang Q, Laforest L, Yin DD, Nocea G, Sazonov Kocevar V. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med. 2006;100:140–7.CrossRef
4.
go back to reference Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRef Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRef
5.
go back to reference Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–38.CrossRef Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–38.CrossRef
6.
go back to reference Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897–906.CrossRef Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897–906.CrossRef
7.
go back to reference Tay TR, Hew M. Comorbid, “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73(7):1369–82.CrossRef Tay TR, Hew M. Comorbid, “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73(7):1369–82.CrossRef
9.
go back to reference Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7.CrossRef Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7.CrossRef
10.
go back to reference Nathan RA, Sorkness CA, Kosinki M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.CrossRef Nathan RA, Sorkness CA, Kosinki M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.CrossRef
11.
go back to reference Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265–70.CrossRef Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265–70.CrossRef
12.
go back to reference Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRef
13.
go back to reference Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ATS/ERS task force. general considerations for lung function testing. Eur Respir J. 2005;26:153–61.CrossRef Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ATS/ERS task force. general considerations for lung function testing. Eur Respir J. 2005;26:153–61.CrossRef
14.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS task force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS task force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef
15.
go back to reference Paggiaro PL, Dente FL, Morelli MC, Bancalari L, Di Franco A, Giannini D, et al. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med. 1994;149:1447–51.CrossRef Paggiaro PL, Dente FL, Morelli MC, Bancalari L, Di Franco A, Giannini D, et al. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med. 1994;149:1447–51.CrossRef
16.
go back to reference Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl. 2002;37:1–2.CrossRef Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl. 2002;37:1–2.CrossRef
17.
go back to reference Cianchetti S, Bacci E, Ruocco L, Bartoli ML, Carnevali S, Dente FL, et al. Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline-induced sputum in asthmatic subjects. Clin Exp Allergy. 1999;29:712–8.CrossRef Cianchetti S, Bacci E, Ruocco L, Bartoli ML, Carnevali S, Dente FL, et al. Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline-induced sputum in asthmatic subjects. Clin Exp Allergy. 1999;29:712–8.CrossRef
18.
go back to reference Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med. 2000;162:1172–4.CrossRef Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med. 2000;162:1172–4.CrossRef
19.
go back to reference American Thoracic Society Documents. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–30.CrossRef American Thoracic Society Documents. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–30.CrossRef
20.
go back to reference Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:1–298. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:1–298.
21.
go back to reference ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812–8.CrossRef ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812–8.CrossRef
22.
go back to reference Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, et al. Institute’s severe asthma research program. identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315–23.CrossRef Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, et al. Institute’s severe asthma research program. identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315–23.CrossRef
23.
go back to reference van Veen IH, ten Brinke A, Sterk PJ, Rabe KF, Bel EH. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy. 2008;63:570–4.CrossRef van Veen IH, ten Brinke A, Sterk PJ, Rabe KF, Bel EH. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy. 2008;63:570–4.CrossRef
24.
go back to reference Amelink M, Hashimoto S, Spinhoven P, Pasma HR, Sterk PJ, Bel EH, ten Brinke A. Anxiety, depression and personality traits in severe, prednisone-dependent asthma. Respir Med. 2014;108:438–44.CrossRef Amelink M, Hashimoto S, Spinhoven P, Pasma HR, Sterk PJ, Bel EH, ten Brinke A. Anxiety, depression and personality traits in severe, prednisone-dependent asthma. Respir Med. 2014;108:438–44.CrossRef
25.
go back to reference Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–8.CrossRef Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–8.CrossRef
26.
go back to reference Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107:73–80.CrossRef Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107:73–80.CrossRef
27.
go back to reference ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109:621–6.CrossRef ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109:621–6.CrossRef
28.
go back to reference Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12:272–6.CrossRef Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12:272–6.CrossRef
29.
go back to reference Lamblin C, Gosset P, Salez F, Vandezande LM, Perez T, Darras J, et al. Eosinophilic airway inflammation in nasal polyposis. J Allergy Clin Immunol. 1999;104:85–92.CrossRef Lamblin C, Gosset P, Salez F, Vandezande LM, Perez T, Darras J, et al. Eosinophilic airway inflammation in nasal polyposis. J Allergy Clin Immunol. 1999;104:85–92.CrossRef
30.
go back to reference Guida G, Rolla G, Badiu I, Marsico P, Pizzimenti S, Bommarito L, et al. Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest. 2010;137:658–64.CrossRef Guida G, Rolla G, Badiu I, Marsico P, Pizzimenti S, Bommarito L, et al. Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest. 2010;137:658–64.CrossRef
31.
go back to reference Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.CrossRef Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.CrossRef
32.
go back to reference Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, on behalf of the Lansoprazole Asthma Study Group. Effect of 24 weeks of Lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128:1128–35.CrossRef Littner MR, Leung FW, Ballard ED, Huang B, Samra NK, on behalf of the Lansoprazole Asthma Study Group. Effect of 24 weeks of Lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128:1128–35.CrossRef
33.
go back to reference Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of Esomeprazole for treatment of poorly controlled asthma; a randomized controlled trial. N Engl J Med. 2009;360:1487–99.CrossRef Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of Esomeprazole for treatment of poorly controlled asthma; a randomized controlled trial. N Engl J Med. 2009;360:1487–99.CrossRef
34.
go back to reference Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, Hew M. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21:1384–90.CrossRef Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, Hew M. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21:1384–90.CrossRef
36.
go back to reference Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545–54.CrossRef Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545–54.CrossRef
37.
go back to reference Chipps BE, Haselkorn T, Paknis B, et al. More than a decade follow-up in patients with severe or difficult-to-treat asthma: the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) II. J Allergy Clin Immunol. 2018;141(5):1590–7.CrossRef Chipps BE, Haselkorn T, Paknis B, et al. More than a decade follow-up in patients with severe or difficult-to-treat asthma: the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) II. J Allergy Clin Immunol. 2018;141(5):1590–7.CrossRef
Metadata
Title
Comorbidities are associated with different features of severe asthma
Authors
Federica Novelli
Elena Bacci
Manuela Latorre
Veronica Seccia
Maria Laura Bartoli
Silvana Cianchetti
Federico Lorenzo Dente
Antonella Di Franco
Alessandro Celi
Pierluigi Paggiaro
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2018
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/s12948-018-0103-x

Other articles of this Issue 1/2018

Clinical and Molecular Allergy 1/2018 Go to the issue